Zelimei (benvimod) / Shanghai Thederma Pharmaceuticals - LARVOL DELTA

Itching control and long-term remission of atopic dermatitis by TAP1503 (SID 2025) - "During the extended follow-up, approximately 70% of participants in the experimental group did not experience any AD flare-ups after discontinuing treatment, up to the 52-week endpoint. In conclusion, this first and only study in China to use tapinarof (TAP1503) for treating AD-associated pruritus and examining its long-term effects demonstrates that it provides rapid relief and may extend the duration of remission."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • TAP1